title: [Treatment of adrenocortical carcinomas is challenging].
abstract: Adrenocortical carcinomas (ACC) are rare tumours responsible for only 0.02% of the total number of malignant diseases. However the ACC are aggressive with a mean fiveyears survival of 20-50% and are often associated with increased production of adrenocortical hormones. The effect of the treatment is controversial and often based on small retrospective series or expert opinions. Centralization, international attention and collaboration in the treatment of ACC are mandatory. Randomized clinical trials are needed to determine the best treatment strategy in order to increase survival in patients with ACC.
authors: Onkologisk Klinik 5073, Rigshospitalet, 2100 København Ø, Denmark.
authors: Julie
authors: J
authors: Abildgaard
authors: Helle
authors: H
authors: Pappot
authors: Peter Meidahl
authors: PM
authors: Petersen
authors: Mikael
authors: M
authors: Rørth
authors: Åse Krogh
authors: ÅK
authors: Rasmussen
authors: Birgitte Grønkær
authors: BG
authors: Toft
authors: Peter
authors: P
authors: Sommer
authors: Gedske
authors: G
authors: Daugaard
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D018268:Adrenocortical Carcinoma / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D012307:Risk Factors; D014057:Tomography, X-Ray Computed